Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia

    ... therapy (IST). The management of patients with refractory SAA after IST is a major challenge. Alternative donor BMT is best chance for cure in refractory SAA, but morbidity and mortality from graft failure and ... safely expand the donor pool in 16 consecutive patients with refractory SAA who did not have a matched sibling donor. Between July 2011 and ...

    Research Article last updated 01/24/2017 - 10:04am.

  2. Good riddance to the term "refractory anemia" in myelodysplastic syndromes

    ... The term " refractory anemia " was used in 1937 by Cornelius Parker Rhoads to ... the World Health Organization (WHO) proposed elimination of "refractory anemia" in a more general proposal for reclassification of myeloid ...

    Research Article last updated 11/02/2016 - 9:37am.

  3. Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Achieved Outcomes Comparable With Matched Unrelated Donor Transplantation in Young Acquired Severe Aplastic Anemia

    ... patients MUDs for HSCT. Most were heavily transfused and refractory to previous immunotherapy. The median durations for myeloid ...

    Research Article last updated 06/13/2018 - 2:28pm.

  4. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia

    ... Limited therapies exist for patients with refractory and relapsed (RR) higher-risk myelodysplastic syndromes ...

    Research Article last updated 11/02/2016 - 9:17am.

  5. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

    ... without del(5q), but its efficacy in patients clearly refractory to erythropoiesis-stimulating agents (ESA) is not known. We ... consecutive lower-risk non-del(5q) MDS patients with anaemia refractory to ESA and treated with LEN in a compassionate programme, 20 of whom ...

    Research Article last updated 04/24/2012 - 2:47pm.

  6. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia

    ... from 2003-2010 in treatment-naïve, relapsed, and refractory SAA in three separate research protocols at the National ... Primary outcome was hematologic response at 6 months. For refractory disease, patients were randomized between rabbit ATG plus ... in SAA but best results are obtained in the relapsed and refractory settings. The trials were registered at www.clinicaltrials.gov ...

    Research Article last updated 11/16/2011 - 1:57pm.

  7. Alternative donor HSCT in refractory acquired aplastic anemia - Prevention of graft rejection and graft versus host disease by immunoablative conditioning and graft manipulation

    ... H, Müller E, Schwinger W. Alternative donor HSCT in refractory acquired aplastic anemia - Prevention of graft rejection ... IST. Seven patients (median age at diagnosis, 11 yr) with refractory AAA without a MSD underwent HSCT from matched unrelated (n = 6) ...

    Research Article last updated 07/30/2012 - 2:02pm.

  8. Eltrombopag and improved hematopoiesis in refractory aplastic anemia

    ... One third of patients have disease that is refractory to immunosuppression, with persistent, severe cytopenia ... 2 study involving patients with aplastic anemia that was refractory to immunosuppression to determine whether the oral thrombopoietin ...

    Research Article last updated 07/31/2012 - 2:24pm.

  9. Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors

    ... marrow failure syndrome and hypocellular refractory cytopenia of childhood (RCC). Historically, patients ...

    Research Article last updated 03/02/2015 - 12:42pm.

  10. Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.

    ... constitute the "previously treated" and "relapsed/ refractory " MDS populations, and how specifically to define disease ...

    Research Article last updated 10/11/2011 - 5:58pm.